Credit Suisse’s PDS Biotechnology PDSB Stock Holding History

Credit Suisse’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-679	Closed	-$146K	–	4152
2017 Q3	$146K	Buy	+679	New	+$140K	﹤0.01%	4013

Other funds holding PDSB

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Credit Suisse's PDSB Position: Q4 2017 in Review

Credit Suisse sold out of PDS Biotechnology (PDSB) in Q4 2017, closing a stake of 679 shares — an estimated $146K sold.

Credit Suisse first reported a position in PDSB in Q3 2017 and held it in 1 quarter. The position peaked at $146K in Q3 2017. 57 funds tracked by Wall St. Rank hold PDSB as of Q4 2017.

Credit Suisse reported no remaining PDS Biotechnology position as of Q4 2017 after selling out during the quarter.
Credit Suisse sold 679 PDS Biotechnology shares in Q4 2017, an estimated $146K.
Credit Suisse first reported a position in PDS Biotechnology in Q3 2017 and held it in 1 quarter.
Credit Suisse's PDS Biotechnology position peaked at $146K in Q3 2017.
57 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2017.

Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.